$17M Grant to Cut Tuberculosis Treatment Time in Half

Imagine taking antibiotics every single day for six months straight, dealing with serious side effects, while facing social stigma and mounting medical bills. That's the reality for tuberculosis patients worldwide, and it's about to change.

Researchers at Weill Cornell Medicine received $17.4 million from the National Institute of Allergy and Infectious Diseases to find ways to dramatically shorten TB treatment. The infectious disease still ranks among the top 10 killers globally, claiming lives not because we lack a cure, but because the current treatment is so grueling that many patients give up halfway through.

"The current regimen works, but the drugs are far from ideal and must be taken over four to six months," said Dr. Kyu Rhee, co-principal investigator and professor of medicine at Weill Cornell. When patients stop treatment early because they feel better or can't afford to continue, the bacteria can come roaring back, often in drug-resistant forms that are much harder to cure.

This new five-year project brings together teams of scientists with different specialties to attack the problem from multiple angles. Dr. Dirk Schnappinger will use a special gene silencing system to find ways to actually kill TB bacteria instead of just stopping their growth. Dr. Rhee's team will study two common antibiotics to see if their mechanisms can be tweaked to work faster.

Meanwhile, Dr. Jeremy Rock at Rockefeller University will map genetic interactions in TB bacteria to find their weak spots. Dr. Carl Nathan will identify genes the bacteria need to survive in real human bodies, not just laboratory dishes.

The scientists will use cutting-edge single-cell technologies and machine learning to watch how individual bacteria respond to drugs. This could reveal hidden populations of bacteria that make treatment take so long.

The Ripple Effect

Shortening TB treatment isn't just about convenience. When patients can't complete their months-long therapy, they can spread drug-resistant bacteria to others in their communities. A cure that takes weeks instead of months means more people finish treatment, fewer relapses, less drug resistance, and ultimately fewer deaths from a disease that's been plaguing humanity for thousands of years.

Weill Cornell has been at the forefront of TB research for over 50 years, steadily reducing treatment from a year and a half to several months. This grant writes the next chapter in that story, bringing together genomics, metabolomics, bioinformatics, and clinical expertise to solve a puzzle that's stumped researchers for decades.

A shorter, safer cure for tuberculosis could transform global health within our lifetime.